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1. Introduction
Diabetes and cancer are two common conditions. Many epidemiological studies suggest
frequent co-occurrence of diabetes and cancer. Meta-analyses and the summary of recom‐
mendations from the American Diabetes Association (ADA) and American Cancer Society
suggest association of cancer and diabetes including liver, pancreas, endometrial, colorectal,
breast and bladder cancers.[1] Diabetes appears to protect against prostate cancer based on
decreased incidence of prostate cancer in subjects with diabetes. Lung cancer appears not to
be associated with diabetes, and data is inconclusive for renal cell cancer and lymphoma.[1]
Most of the association data is on the relation of cancer to type 2 diabetes. The major concern
is that type 2 diabetes is associated with three of the five leading causes of cancer mortality
such as carcinoma of the colon [2], pancreas [3] and breast (postmenopausal) [4]. The excess
risk for each cancer is ~30% (colon), ~50% (pancreas) and ~20% (breast). The majority of the
epidemiological data on cancer incidence and mortality had been obtained in type 2 diabetic
patients. A cohort study to examine cancer incidence among 29,187 patients in Sweden who
were hospitalized for type 1 diabetes from 1965 through 1999, observed 355 incident cases of
cancer and which corresponded to a 20% increase in overall cancer incidence among type 1
diabetes patients (RR:1.2; CI: 1.0 to 1.3) [5]. Patients with type 1 diabetes had elevated risks of
cancers of the stomach (RR: 2.3; CI: 1.1 to 4.1), cervix (R: 1.6; CI: 1.1 to 2.2), and endometrium
(RR: 2.7; CI: 1.4 to 4.7) [5]. Hyperinsulinemia most likely favors cancer in diabetic patients as
insulin is a growth factor with pre-eminent metabolic as well as mitogenic effects. Insulin
action in malignant cells is favored by mechanisms acting at both the receptor and post-
receptor level. Obesity, hyperglycemia, and increased oxidative stress may also contribute to
increased cancer risk in diabetes [6]. There are reports of concern of hypoglycemic therapies
on cancer risk, especially with insulin analogue-Glargine. A growing body of evidence
suggests that metformin potentially reduces the risk of cancer. Aspirin and non-aspirin non-
steroidal anti-inflammatory drugs appear to reduce recurrence of adenomas and incidence of
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advanced adenomas in individuals with an increased risk of colorectal adenomas and
colorectal cancer, and calcium may reduce recurrence of adenomas [7, 8]. In this chapter we
will include epidemiological evidence of association of diabetes and cancer, possible mecha‐
nisms and the effect of hypoglycemic agents in relation to cancer.
2. Epidemiology of diabetes and cancer risk
The Centers for Disease Control and Prevention (CDC) reports that 25.8 million people (8.3%
of the U.S. population) have diabetes. Among them, 18.8 million people have diagnosed
diabetes and 7.0 million people have undiagnosed diabetes. http://www.cdc.gov/diabetes/
pubs/estimates11.htm#1. Three hundred and forty six million people worldwide have
diabetes. Type 2 diabetes comprises 90% of people with diabetes around the world, and is
largely the result of excess body weight and physical inactivity. http://www.who.int/media‐
centre/factsheets/fs312/en/index.html. The incidence of diabetes is increasing globally. The
estimated incidence of 12.7 million new cancer cases in 2008 will rise to 21.4 million by 2030,
with nearly two thirds of all cancer diagnoses occurring in low- and middle-income countries.
http://www.who.int/nmh/publications/ncd_report_chapter1.pdf. A series of recent studies
and meta-analyses confirm that the risk for several solid and hematologic malignancies
(including liver, pancreas, colorectal, kidney, bladder, endometrial and breast cancers, and
non-Hodgkin's lymphoma) is increased in patients with diabetes [6]. Here the discussion
follows on each malignancy with increased frequency in diabetes.
2.1. Pancreatic cancer
Type 2 diabetes mellitus is considered to be the third modifiable risk factor for pancreatic
cancer after cigarette smoking and obesity. Based on the meta-analysis of 36 case–control and
cohort studies, Everhart and Wright reported that the age and sex adjusted odds ratio for the
development of pancreatic cancer in people with diabetes was 1.8 (CI of 1.7–1.9) [9]. They also
noted that increased frequency of pancreatic cancer occurs with long-standing diabetes,
especially those with the duration of at least 5 years with a RR of 2.0 with CI of 1.2 to 3.2 [9].
Gallo et al [10] from Italy reported that 40.2% of patients with pancreatic cancer and diabetes
were diagnosed concomitantly or 15.9% were diagnosed within two years prior to diagnosis
of cancer. Based on the data, the authors concluded increased prevalence of diabetes is related
to pancreatic cancer and the diabetes is caused by the tumor [10]. A causal relationship between
diabetes and pancreatic cancer is also supported by findings from pre-diagnostic evaluations
of glucose and insulin levels in prospective studies. Data show that up to 80% of patients with
pancreatic cancer are either hyperglycemic or diabetic. Diabetes has been shown to improve
after pancreatic-cancer resection, suggesting that diabetes is caused by the cancer [11]. Pannala
et al suggest new-onset diabetes may indicate subclinical pancreatic cancer, and patients with
new-onset diabetes may constitute a population in whom pancreatic cancer can be detected
early [11]. A meta-analysis of three cohorts and six case-control studies revealed even a two-
fold risk in type 1 diabetes patients [12]. A meta-analysis of 36 studies was carried out by
Huxley and associates that included17 case-control and 19 cohort or nested case-control studies
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with information on 9220 individuals with pancreatic cancer [3]. They noted that individuals
with recent diagnosis of diabetes (< 4 years) had a 50% greater risk of the malignancy compared
with individuals who had diabetes for ≥ 5 years (OR 2.1 vs. 1.5; p = 0.005).
2.2. Colorectal cancer
Increasing evidence suggests that a history of diabetes mellitus (DM) may be associated with
an increased risk of colorectal cancer (CRC). In 2005, meta-analyses of 15 studies (six case-
control and nine cohort studies) in the USA and Europe, including 2 593 935 participants,
Larsson and associates found that diabetes was associated with an increased risk of colorectal
cancer, compared with no diabetes (RR: 1.30; CI: 1.20–1.40] [2]. These results were said to be
consistent between case-control and cohort studies and across the United States and Europe.
The association did not differ significantly by sex, or by cancer sub-site. Diabetes was positively
associated with colorectal cancer mortality. Results from a meta analysis of 41 cohorts was
reported to support that diabetes was associated with an increased incidence of CRC (RR:
1.27;1.21-1.34) [13]. In a recent systematic review and meta-analysis, twenty-four studies
including eight case-control and 16 cohort studies, with a total of 3,659,341 participants were
included [14]. Meta-analysis of the 24 included studies indicated that diabetes was associated
with an increased risk of colorectal cancer, compared with no diabetes (RR: 1.26; CI: 1.20-1.31),
without heterogeneity between studies (p (heterogeneity) = 0.296). Sub-group analyses found
that these results were consistent between case-control and cohort studies and among studies
conducted in different areas. The association between diabetes and colorectal cancer incidence
did not differ significantly by sex and sub-sites. Insulin therapy was also positively associated
with risk of colorectal cancer (RR = 1.61; 1.18-1.35), with evidence of heterogeneity between
studies (p (heterogeneity) = 0.014).
2.3. COX-2 and colon cancer
Although COX-2, the inducible isoform, is regularly expressed at low levels in colonic mucosa,
its activity increases dramatically following mutation of the adenomatous polyposis coli (APC)
gene, suggesting that β-catenin/T cell factor-mediated Wnt signaling activity may regulate
COX-2 gene expression. In addition, hypoxic conditions and sodium butyrate exposure may
also contribute to COX-2 gene transcription in human cancers [15]. Because of its role in
carcinogenesis, apoptosis, and angiogenesis, it is an excellent target for developing new drugs
with selectivity for prevention and/or treatment of human cancers [16].
2.4. Breast cancer
Meta-analyses of 20 studies (5 case-control and 15 cohort studies) by Larsson and associates
found that women with diabetes had a statistically significant 20% increased risk of breast cancer
(RR, 1.20; CI:1.12-1.28) compared with no diabetes [4]. The summary estimates were similar for
case-control studies (RR, 1.18; CI: 1.05-1.32) and cohort studies (RR, 1.20; CI: 1.11-1.30). Meta-
analysis of 5 cohort studies on diabetes and mortality from breast cancer yielded a summary
RR of 1.24 and CI of 0.95-1.62 for women with versus without diabetes. Findings from this meta-
analysis indicate that diabetes is associated with an increased risk of breast cancer [4]. In the
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Nurses' Health Study, a total of 87,143 postmenopausal women, aged 30 to 55 years and free of
cancer, were followed up for up to 26 years (1976-2002) and evaluated for the incidence of
invasive breast cancer with increase in weight of at least 25.0 kg or more since age 18 years.
Eliassen and associates noted an increased risk of breast cancer (RR: 1.45; CI: 1.27-1.66; p <.
001),  with a  stronger association among women who have never taken postmenopausal
hormones (RR, 1.98; CI: 1.55-2.53). Data suggest that weight gain during adult life, specifical‐
ly since menopause, increases the risk of breast cancer among postmenopausal women, whereas
weight loss after menopause is associated with a decreased risk of breast cancer [17].
1. Non-modifiable risk factors:
a. Age
b. Sex
c. Ethnicity
2. Modifiable risk factors:
a. Overweight/obesity
b. Physical activity
c. Diet
3. Biological links:
a. Hyperglycemia
b. Insulin
c. IGF-1
d. Estrogen and androgen bioavailability
e. Cytokines
Table 1. Risk factors common to both diabetes and cancer
3. Pathophysiology
3.1. Hyperinsulinemia and cancer
Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor
with pre-eminent metabolic but also mitogenic effects, and its action in malignant cells is
favored by mechanisms acting at both the receptor and post-receptor level. Obesity, hyper‐
glycemia, and increased oxidative stress may also contribute to increased cancer risk in
diabetes [6].
3.2. Insulin
Insulin resistance and hyperinsulinemia are important factors in the development of type 2
diabetes. Insulin is known to stimulate cell proliferation and injection of insulin in rats
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promoted carcinogen-induced colon cancer [18]. Insulin/insulin-like growth factor 1(IGF-1)
receptors and G protein-coupled receptors (GPCR) signaling systems are implicated in
autocrine-paracrine stimulation of a variety of malignancies, including ductal adenocarcinoma
of the pancreas. Metformin, the most widely used drug in the treatment of type 2 diabetes,
activates AMP kinase (AMPK), which negatively regulates mammalian target of rapamycin
(mTOR) complex 1 (mTORC1) [19]. Metformin was shown to significantly decrease the growth
of pancreatic cancer cells xenografted into the flank of nude mice by interrupting the G protein-
coupled receptor (GPCR), insulin receptor signaling by down-regulating the mTOR pathway
[20]. The GPCR and insulin receptor pathways are associated with increased DNA synthesis
and pancreatic cancer cell growth. By negatively regulating GPCR and insulin receptor
signally, and interrupting their cross talk, metformin is shown to decrease pancreatic cancer
cell growth in mice. In a meta-analysis of epidemiological studies on markers of hyperinsuli‐
nemia and cancer, Pisani reported that subjects who develop colorectal and pancreatic cancers
have increased pre-diagnostic blood levels of insulin and glucose [21]. High insulin levels have
also been shown to be associated with risk of endometrial cancer independent of estradiol [22].
A link between breast cancer risk and hyperinsulinemia (measured by fasting C-peptide levels)
has been shown mainly in postmenopausal breast cancer. Insulin levels were positively
associated with endometrial carcinoma [HR: 2.33, CI: 1.13-4.82] among women not using
hormone therapy [23].
3.3. Insulin resistance
The term insulin resistance denotes that action of insulin is impaired in peripheral target tissues
that include skeletal muscle, liver, and adipose tissue. Recent literature supports the hypoth‐
esis that insulin resistance is a high risk for cancers. The molecular mechanisms for this
association and the role in the neoplastic transformation process are being explored. Insulin
is a major anabolic hormone that can stimulate cell proliferation. Adiposity induces adverse
local and systemic effects that include adipocyte intracellular lipid accumulation, endoplasmic
reticulum and mitochondrial stress, and insulin resistance, with associated changes in
circulating adipokines, free fatty acids, and inflammatory mediators. Insulin resistance and
associated hyperglycemia, hyperinsulinemia, and inflammation have been suggested to be the
underlying mechanisms contributing to development of diabetes-associated pancreatic cancer.
Hyperinsulinemia, insulin resistance and proinflammatory cytokines have been linked to
neoplastic proliferation of various organ cells (Fig. 1).
In a study of the Polyp Prevention Trial of insulin and fasting glucose and risk of recurrent
colorectal adenomas, Flood et al. noted the association of increased risk of adenoma recurrence
and risk for recurrence of advanced adenomas with increased insulin [24].
3.4. Insulin-like Growth Factor-1 (IGF-1) and cancer
The IGF (insulin-like growth factor) system is essential for physiological growth. The IGF
complex includes IGF-1 and IGF-2, their corresponding receptors (IGFR-1 and IGFR-2), IGF
binding proteins 1–6 (IGFBPs), insulin receptor substrate (IRS). The signaling pathway of IGF
plays a critical role in cellular proliferation and inhibition of apoptosis. Though growth
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hormone is the primary stimulus for IGF-1 production in the liver and insulin can increase the
IGF-1 production by up-regulating growth hormone receptors in the liver, hyperinsulinemia
can also increase IGF-1 bioavailability by decreasing hepatic secretion of IGF-binding protein
(IGFBP)-1 and −2 [25]. IGF-R, a tyrosine kinase receptor for IGF-I and IGF-II is said to play a
role in malignant transformation, progression, protection from apoptosis, and metastasis as
documented in cell culture, animal and human studies [26]. Since the expression of IGF-1
receptors occurs in several cancers, the effects of insulin on cancer cell proliferation in vivo may
involve IGF-1 stimulation and indirectly stimulate cancers. The IGF signaling pathway is
involved in cell proliferation and differentiation and inhibits apoptosis. Increased expression
of IGF-1, IGF-2, IGF-1R, or combinations have been documented in various malignancies
including glioblastomas, neuroblastomas, meningiomas, medulloblastomas, carcinomas of the
breast, malignancies of the gastrointestinal tract, such as colorectal and pancreatic carcinomas,
and ovarian cancer [27]. Higher IGF-1 levels were reported to be associated with increased
colorectal adenoma risk (ORs = 1.58; 1.16-2.16),[28] and inversely associated with endometrial
carcinoma (HR: 0.53; 0.31-0.90) [23].
3.5. Adiponectin and cancer
Adiponectin, which is also referred to as ACP30 (Acrp30), is secreted predominantly by white
adipose tissue [29]. Circulating concentrations of adiponectin are reduced in obesity and type
2 diabetes [30-32]. Adiponectin is considered to have beneficial antineoplastic effects, which
are believed to be due to anti-proliferative, anti-inflammatory effects, along with antagonizing
insulin resistance [33]. Adiponectin has been found to be an important negative regulator of
Figure 1. Insulin resistance and premenopausal breast cancer. Abbreviations: SHBG, sex hormone-binding globulin;
IGF, insulin-like growth factor; GH, growth hormone; HDL, high-density lipoprotein cholesterol.
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hematopoiesis and the immune system as adiponectin was shown to suppress the growth of
myelomonocyte cell lines in vitro by inducing apoptosis in myelomonocytic progenitor cells
(leukaemia lines) and modulating expression of apoptosis-related genes and down regulating
Bcl-2 gene expression [34]. Epidemilogical data have also shown a link between low adipo‐
nectin levels and renal cell cancer [35, 36]; especially large tumor size [37, 38]. Adiponectin was
inversely associated with non-Hodgkin lymphoma and acute myeloblastic leukaemia (OR:
0.56; 0.34-0.94), but not with acute lymphoblastic leukaemia of B or T cell [39]. In a number of
epidemiological studies, adiponectin levels have been linked to breast cancer and are believed
to inhibit breast cancer cell proliferation in vivo. This effect may be due to adiponectin-triggered
cellular apoptosis in MDA-MB-231 breast cancer cells in the presence of 17β-estradiol. These
findings may suggest that a cross-talk between adiponectin and estrogen receptor signaling
exists in breast cancer cells and that adiponectin effects on the growth and apoptosis of breast
cancer cells in vitro are dependent on the presence of 17β-estradiol [40]. Low serum adiponectin
is associated with colon, prostate and breast cancer [41]. In a recent study, plasma adiponectin
level was associated with decreased colorectal cancer risk [42].
Adiponectin and colorectal cancer: Adiponectin was shown to act on preneoplastic colon
epithelial cells to regulate cell growth by inducing autocrine IL-6 production and trans-IL-6
signaling. In a prospective case control study, men with low plasma adiponectin levels were
said to have a higher risk of colorectal cancer than men with higher levels [43]. Meta analysis
of 13 studies in patients with colorectal cancer and adenoma, though there was significant
heterogeneity among studies, noted that there was a negative dose response relationship
between levels of adiponectin and the risk of colorectal neoplasm in men [44].
Adiponectin and Endometrial cancer: Circulating adiponectin concentrations are inversely
correlated with the incidence of endometrial carcinoma in epidemiological studies. In a study
that investigated the direct effects of adiponectin on two endometrial carcinoma cell lines,
HEC-1-A and RL95–2, adiponectin treatment led to suppression of cell proliferation in both
cell types, which was primarily believed to be due to the significant increase of cell populations
at G1/G0 phase and secondary to the induction of apoptosis [45].
3.6. Obesity and cancer
Accumulating epidemiologic evidence shows that obesity is associated with an increased risk
of several common adult cancers. The risk of diabetes increases linearly with BMI; the
prevalence of diabetes increased from 2% in those with a BMI of 25 to 29.9 kg/m2, to 8% in
those with a BMI of 30 to 34.9 kg/m2, and finally to 13% in those with a BMI greater than 35
kg/m2 [46]. Similarly, an association between obesity or an incremental increase in body mass
index (BMI) and an increased cancer risk have been reported for colon cancer (men and
women) and rectal cancer (men only),[47] colon cancer,[48] liver cancer,[49] gall bladder
cancer,[50] multiple myeloma, non-Hodgkin's lymphoma,[51] pancreatic cancer,[52] leuke‐
mia,[53] ovarian cancer,[54] breast cancer,[55] and endometrial cancer [56, 57]. In a population
based prospective study of more than 900,000 U.S. adults, the reported relative risk of cancers
in overweight and obesity was 1.52 for men and 1.62 for women [18]. A study from the United
Diabetes and Cancer
http://dx.doi.org/10.5772/56419
239
Kingdom showed that increasing BMI was associated with an increased incidence of endo‐
metrial cancer (RR:2.89, CI: 2.62–3.18), adenocarcinoma of the esophagus (RR:2.38;CI: 1.59–
3.56), kidney cancer (RR:1.53, CI: 1.27–1.84), leukemia (RR:1.50, CI:1.23–1.83), multiple
myeloma (RR:1.31;CI: 1.04–1.65), pancreatic cancer (RR:1.24;CI: 1.03–1.48), non-Hodgkin's
lymphoma (RR:1.17; CI: 1.03–1.34), ovarian cancer (RR: 1.14; CI: 1.03–1.27), all cancers com‐
bined (RR:1.12; CI:1.09–1.14), breast cancer in postmenopausal women (RR: 1.40; CI: 1.31–1.49),
and colorectal cancer in premenopausal women (RR:1.61; CI: 1.05–2.48) [58]. It is not surprising
to note that increased adiposity may have a negative effect on treatment outcome and ultimate
survival, because obesity has been found to be a negative prognostic factor for breast can‐
cer[59] and colon cancer [60, 61].
3.7. Cyclooxygenase and cancers
Cyclooxygenase-2 (COX-2) over expression has been found in several types of human cancers,
such as colon, breast, prostate, and pancreas, and appears to control many cellular processes.
The contribution of COX-2 to carcinogenesis and the malignant phenotype of tumor cells have
been thought to be related to its abilities to: (1) increase production of prostaglandins, (2)
convert procarcinogens to carcinogens, (3) inhibit apoptosis, (4) promote angiogenesis, (5)
modulate inflammation and immune function, and (6) increase tumor cell invasiveness [62].
3.8. Proinflammatory cytokines
Adipocytes secrete a number of proinflammatory cytokines. These cytokines are known to
promote insulin resistance and increase circulating TG, features of the metabolic syndrome.
Several cytokines, reactive oxygen species (ROS), and mediators of the inflammatory pathway,
such as activation of nuclear factor-κB (NF-κB) and COX-2, lead to an increase in cell prolif‐
eration, survival, and inhibition of the proapoptotic pathway, ultimately resulting in tumor
angiogenesis, invasion, and metastasis [16]. Proinflammatory cytokines implicated in carci‐
nogenesis include IL-1, IL-6, IL-15, colony-stimulating factors, TNF-α, and the macrophage
migration inhibitory factor.
Macrophage inhibitory cytokine-1 (MIC-1), also known as prostate-derived factor (PDF), is a
molecule of the TGF-β super family and has been associated with the progression of various
types of diseases including prostate cancer [63]. Collectively, cytokines are considered as a
linker between inflammation and cancer. Cytokines, ROS, and mediators of the inflammatory
pathway (e.g., NF-κB and COX-2) have been shown to increase cell cycling, cause loss of tumor
suppressor function, and stimulate oncogene expression and lead to cancers. Positive feedback
mechanisms between estrogens and inflammatory factors may exist in the breast and contrib‐
ute to hormone-dependent breast cancer growth and progression [64]. Prostaglandin E
synthase (PTGES) is also up-regulated by the proinflammatory cytokines TNF-α or IL-1β.
Cytokines can enhance estrogen receptor (ER) activity and PTGES expression through the NF-
κB pathway and cytokines can act to up-regulate aromatase expression as well as 17β-
hydroxysteroid dehydrogenase activity in breast tissue, thereby leading to a further increase
in E2 production [64].
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4. Diabetes therapies and cancer
Diabetes is associated with increased risks of bladder, breast, colorectal, endometrial, kidney,
liver and pancreatic cancer and a lower risk of prostate cancer. Diabetes treatments may
influence the risk of cancer independently of their effect on glycemia. This may complicate the
issues in investigation of the association between diabetes and cancer. Epidemiologic studies
have suggested a protective role for metformin. On the other hand, Glargine, the most widely
used long-acting insulin analogue, may confer a greater risk than other insulin preparations,
particularly for breast cancer. In general, diabetes therapies that are said to be associated with
increased risk of cancer include, use of insulin, sulfonyl urea and DPP4 inhibitors. Diabetes
therapies that are shown benefit by decreasing the cancer risk include use of metformin and
thiazolidinediones. Here we will discuss association of cancer risk with each of the diabetes
therapeutic agents.
4.1. Thiazolidinedione (TZD) and cancer risk in type 2 diabetes
TZDs are reported to decrease in cancer both in clinical data series and in vitro studies. In
addition pioglitazone, one of the TZDs, was shown to increase the risk of bladder cancer in
those with the use for more than 24 months. Based on the randomized clinical trials of
rosiglitazone with duration of >24 weeks that includes eighty trials enrolling 16,332 and 12,522
patients in the rosiglitazone and comparator groups, Monami and associates reported that the
incidence of malignancies was significantly lower with the use of rosiglitazone than in control
groups (RR: 0.23; CI: 0.19–0.26) vs. RR of 0.44(CI:0.34–0.58) cases/100 patient-years; p < 0.05)
[65]. In a study using the diabetes registry of Hong Kong, Yang and associates reported that
TZD usage was associated with 83% reduction in cancer risk in Chinese patients with type 2
diabetes in a dose–response manner [66]. Using the Taiwan National Health Insurance claims
database, significantly lower risk of liver cancer incidence was found for any use of rosiglita‐
zone or pioglitazone; use of rosiglitazone but not pioglitazone was associated with decreased
incidence of colorectal cancer [67].
4.2. Pioglitazone and bladder cancer
Using the Kaiser Permanente Northern California diabetes registry with 193,099 patients who
were ≥40 years of age between 1997 and 2002, excluding those with prior bladder cancer, 30,173
patients treated with pioglitazone were identified. In this cohort of patients with diabetes,
short-term use of pioglitazone was not associated with an increased incidence of bladder
cancer, but use for more than 2 years was weakly associated with increased risk [68]. 
Using the general practice research database in the United Kingdom, use of pioglitazone more
than 24 months was reported to be associated with an increased risk of incident bladder cancer
among people with type 2 diabetes [69. Using data from the French national health insurance
information system, in a population based study, pioglitazone use of more than 24 months
was reported significantly associated with increased risk of bladder cancer [70].
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4.3. Metformin
Studies of patients with T2DM on metformin have demonstrated a lower risk of cancer [71-74].
In a recent study of the influence of treatment with metformin on survival after cancer
diagnosis by Currie and associates, metformin was shown to be associated with survival
benefit both in comparison with other treatments for diabetes and in comparison with a non-
diabetic population [75]. An observational cohort study from the United Kingdom suggested
that metformin use may be associated with a reduced risk of cancer (HR:0.63 (0.53-0.75) [72].
The study noted that the reduced risk was after adjusting for sex, age, BMI, A1C, smoking,
and other drug use [72]. In a different database study from UK general practices, metformin
use was reported to be associated with lower risk of cancer of the colon or pancreas, but did
not affect the risk of breast or prostate cancer [71]. Metformin use was associated with survival
benefit in comparison with other treatments for diabetes and also in comparison with a non-
diabetic population [75]. Metformin has been associated with reduced risk of pancreatic cancer
in diabetics and recognized as an antitumor agent with the potential to prevent and treat this
cancer [76]. A retrospective cohort study to investigate the survival benefit of metformin in
patients with diabetes and pancreatic malignancy, from the MD Anderson Cancer Center from
2000 to 2009, reported that metformin users have a significant survival benefit compared to
non-users (the median survival 16.6 vs. 11.5 months; p = 0.0044) [77]. They also report a 33%
decrease risk of death in patients who used metformin (HR: 0.67; p = 0.005) [77]. This implies
that metformin may have some beneficial effects on slowing the progression of pancreatic
malignancy. However, specific pathogenesis is unclear and would have to be further explored.
In an interesting finding from a data base study from Hong Kong, nonusers of metformin with
low HDL cholesterol had an adjusted hazard ratio of 5.75 (CI: 3.03-10.90) compared with HDL
cholesterol ≥ 1.0 mmol/L plus use of metformin [78]. The reduction in cancer risk with the use
of metformin in patients with type 2 diabetes is said to be dose related [74]. In a Canadian
population-based cohort study, Bowker and associates noted that patients with type 2 diabetes
exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-
related mortality compared with patients exposed to metformin [79]. In addition they also
noted that, the sulfonylurea cohort had greater cancer-related mortality compared with the
metformin cohort after multivariate adjustment [79]. There are several in vitro and in vivo
studies from cell lines and animal models support the benefit of metformin against cancer.
There are several ongoing trials to examine the clinical outcomes.
4.3.1. Metformin and individual cancers
Long term use of metformin was shown to decrease risk of breast cancer in female patients
with type 2 diabetes [80]. In a case-control study using the U.K.-based General Practice
Research Database, metformin use was associated with an adjusted odds ratio of 0.44 (CI:
0.24-0.82) for developing breast cancer compared with no use of metformin [81]. In a similar
study from the UK, long-term use of ≥ 40 prescriptions (>5 years) of metformin, based on 17
exposed case patients and 120 exposed control patients, was associated with an adjusted odds
ratio of 0.44 (95% CI 0.24-0.82) for developing breast cancer compared with no use of metformin
[80]. A meta-analysis of 17 case-control studies and 32 cohort studies of diabetes and hepato‐
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cellular carcinoma, metformin treatment was potentially protective [82]. In a meta- analysis of
five studies comprising 108,161 patients with type 2 diabetes, metformin therapy appears to
be associated with a significantly lower risk of colorectal cancer in patients with type 2 diabetes
[82].
4.3.2. Mechanism of metformin in reducing cancer
It has been postulated that the effect of metformin on cancer development and progression
may be a result of decreased levels of insulin [83] and insulin resistance. However, the possible
anticancer effect of metformin is believed to be mediated by the inhibition of mitochondrial
oxidative phosphorylation leading to activated AMPK pathway or independent of non-AMPK
pathway. Human breast cancer cells treated with metformin demonstrate inhibited prolifera‐
tion and colony formation and increased cell cycle arrest [84]. Studies have shown that
metformin also has a direct effect on tumor cell proliferation [85]. As stated previously,
metformin activates AMPK. The AMPK/mTOR axis is modulated by liver kinase B1 (LKB1).
LKB1 is a tumor suppressor that activates AMPK, leading to mTOR inhibition, resulting in
inhibited cell growth [85]. In vitro studies have shown that treatment with metformin inhibits
cancer cell lines such as breast cancer breast cancer cells,[86] prostate cancer cell lines,[87, 88]
glioma,[89] and fibro sarcoma cell lines [90].
4.4. Therapeutic consideration
4.4.1. Therapeutic considerations in general
Therapeutic considerations need to focus on reduction of the risk factors. Various therapeutic
interventions for weight reduction and healthy life style have been linked to a reduced cancer
risk in the general population. Therapeutic strategies to decrease chronic hyperinsulinemia
and insulin resistance may offer a general approach to prevention of cancer. Metformin is the
insulin sensitizer used primarily in the treatment of type 2 diabetes mellitus.
In a retrospective study of long term benefits of bariatric surgery, a significant decrease in
mortality from cancer-related deaths in the bariatric surgery group compared both with all
subjects and matched subjects with a decrease of 60% for cancer at mean follow-up of 7.1 years.
Anticytokine vaccines, inhibitors of proinflammatory NF-κB and COX-2 pathways, thiazoli‐
dinediones, and antioxidants are potentially useful for the prevention or treatment of pancre‐
atic cancer. Similarly epidemiologic studies have documented a 40–50% reduction in the
incidence of colorectal cancer in individuals taking nonsteroidal anti-inflammatory drugs
(NSAIDs). The long-term use of COX-2-selective inhibitors has, unfortunately, demonstrated
cardiovascular toxicity, so their use in cancer prevention and therapy is currently questionable.
However, there is evidence suggesting that further development of novel COX-2-selective
agents is needed for the prevention and/or treatment of human cancers, especially pancreatic
cancer. Targeting PGE2 signaling by EP receptor antagonists holds promise for the develop‐
ment of targeted therapy for the treatment of cancer [91]. PPARs also play a role in the
regulation of cancer cell growth. Recent evidence suggests that PPAR modulators may have
beneficial effects as chemopreventive agents [92].
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Recent clinical studies with IGF-1R inhibitors have revealed several obstacles to successful use
in cancer therapy. Strategies to inhibit IGF-1R signaling such as tyrosine kinase inhibitors also
disrupt IR signaling, resulting in hyperglycemia and hyperinsulinemia. Several strategies
being considered are based on biomarkers that could identify subpopulations most likely to
be responsive to IGF targeting. The combination therapies with other targeted drugs could
maximize the therapeutic effects of IGF inhibitors [93].
4.4.2. Chemoprevention of colorectal cancer
Of cancers affecting both men and women, colorectal cancer (cancer of the colon and rectum)
is the second leading cancer killer in the United States and the incidence increases with age.
The U.S. Preventive Services Task Force report on the effectiveness of aspirin (ASA), non-
aspirin non steroidal anti-inflammatory drugs (non-ASA NSAIDs), and cyclooxygenase-2
inhibitors (COX-2 inhibitors) for the chemoprevention of colorectal cancer indicate that aspirin
and non-ASA NSAIDs appear to be effective at reducing the incidence of CRAs and CRC [7].
The report also stated that more information is required to clarify the optimal dose, starting
age, and duration of use of ASA since observational studies suggest that higher doses and
prolonged use improve chemo-preventative efficacy. In a recent systematic review and meta-
analysis for randomized controlled trials (RCTs) from United Kingdom, Cooper and associates
identified 44 relevant RCTs and six ongoing studies [8]. They reported that there was a
statistically significant 21% reduction in risk of adenoma recurrence (RR: 0.79; CI: 0.68 to 0.92)
in an analysis of aspirin versus no aspirin in individuals with a history of adenomas or CRC.
In the general population, a significant 26% reduction in CRC incidence was demonstrated in
studies with a 23-year follow-up (RR: 0.74; CI: 0.57 to 0.97). In individuals with a history of
adenomas there was a statistically significant 34% reduction in adenoma recurrence risk (RR:
0.66; CI: 0.60 to 0.72) and a statistically significant 55% reduction in advanced adenoma
incidence (RR 0.45; CI: 0.35 to 0.58). No studies assessed the effect of non-aspirin NSAIDs in
the general population. There was said to be no significant effect of folic acid versus placebo
on adenoma recurrence (RR: 1.16; CI: 0.97 to 1.39) or advanced adenoma incidence in individ‐
uals with a history of adenomas. In the general population there was said to be no significant
effect of folic acid on risk of colorectal cancer (RR: 1.13; CI: CI: 0.77 to 1.64), although studies
were of relatively short duration. Calcium use by familial adenomatous polyposis (FAP)
patients was reported to have no significant reduction in polyp number or disease progression.
In individuals with a history of adenomas there was said to be a statistically significant 18%
reduction in risk of adenoma recurrence (RR: 0.82; CI: 0.69 to 0.98) and a non-significant
reduction in risk of advanced adenomas (RR: 0.77; CI: 0.50 to 1.17). Though these studies are
not selective for subjects with diabetes, prevention of colorectal cancer in subjects with diabetes
is important and relevant.
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